GenOway: Proposal of a new administrator

The Board of Directors of genOway proposes appointing Olivier Charmeil as Administrator

Lyon (France) - May 23, 2022 - genOway (Euronext GrowthTM - ALGEN - ISIN: FR0004053510), a biotechnology company specialized in the design and development of genetically modified research models, is proud to announce that its Board of Directors has proposed the appointment of Mr. Olivier Charmeil, Executive Vice President of Sanofi, to the board to serve as a new independent administrator, subject to a vote at the General Meeting of Shareholders on June 28, 2022.

A graduate of HEC (École des Hautes Etudes Commerciales) and the Institut d'Etudes Politiques (IEP) in Paris, Olivier Charmeil currently oversees the General Medicine entity within the Sanofi Group. He started his career in the Mergers & Acquisitions department of the Banque de l'Union Européenne (European Union Bank), before joining Sanofi in 1994, and became a member of its Executive Committee in 2011, when he was appointed head of Sanofi Pasteur. He has held various positions within Sanofi, most recently as Head of China & Emerging Markets. In June 2020, he was appointed a member of the Board of Directors of the European Federation of Pharmaceutical Industries Associations. He is also a director of the France-China Committee.

With nearly 30 years of experience in the healthcare sector, his understanding of the underlying trends in pharmaceutical research and the culture of continuous innovation, Olivier Charmeil will support genOway in its strategic repositioning over the last few years toward more profitable activities. This transformation is currently taking shape through the development of its range of catalog models in immuno-oncology, which is meeting with great commercial success, and through major innovation projects aimed at mimicking humans and their disease ever more closely to contribute to prevention and cure.

Christian Grenier, chairman of the Board of Directors of genOway, says: "I am very pleased that the Board of Directors of genOway has proposed the appointment of Olivier Charmeil as a new Administrator. His long experience in the pharmaceutical industry and his global and strategic vision on five continents, particularly in Asia, as well as his passion for the development of new innovative and ambitious projects, will be major assets to guarantee the success of of genOway's in-depthtransformation."

Alexandre Fraichard, CEO of genOway, adds: "I would like to warmly thank Olivier Charmeil for his interest in genOway and its history. His future contribution to our Board of Directors will bring new and valuable insights to the entire management team and a deep understanding of our customers' needs so we may be able to respond to them even better. I look forward to this new collaboration to take genOway to a new stage of its development."

www.genOway.com

1

About genOway

Founded in 1999, genOway is a biotechnology company whose goal is to accelerate innovation in medical research by providing researchers and industry with the best research tools. The company specializes in the design, development and commercialization of genetically modified preclinical models, mice, rats and cell lines.

With more than 20 years of expertise in custom-designed models, and a technology platform consisting of exclusive worldwide licenses (CRISPR/Cas9, Smash), genOway has developed, as of 2018, a catalog of ready-to-use "humanized" models for immuno-oncology research and immunotherapies.

Based in Lyon, France, genOway operates in more than 28 countries in North America, Europe and Asia. Among its customers are 380 institutions including the most prestigious academic research laboratories, and 170 life sciences companies, including 17 of the world's top 20 pharmaceutical companies.

genOway is listed on Euronext Paris - Code: ALGEN - ISIN Code: FR0004053510

Investor contact:	Benjamin Bruneau - genOway - [e-mail]
Financial communication:	Mathieu Omnes - Investors - Tél : [phone] - [e-mail]
	Serena Boni - Presse - Tél : [phone] - [e-mail]

The information contained in this communication may contain forward-looking statements that involve risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to risk factors relating to the Company. www.genoway.com.

www.genOway.com

2